# Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.

> **NCT00326326** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 84 (—)

## Conditions studied

- Dyslipidemia

## Interventions

- **DRUG:** CP-778,875

## Key facts

- **NCT ID:** NCT00326326
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** —
- **Final completion:** 2007-06
- **Target enrollment:** 84 (—)
- **Last updated:** 2009-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00326326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00326326, "Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00326326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*